Alterity Therapeutics Ltd (ATHE)

[XenaLives]

From the sticky...

Alterity’s lead candidate, PBT434, is the first of a new generation of small molecules designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. PBT434 has been shown to reduce abnormal accumulation of a-synuclein and tau proteins in animal models of disease by restoring normal iron balance in the brain. In this way, it has excellent potential to treat various forms of atypical Parkinsonism.

A more practical solution may be enabling natural autophagy, which AVXL Blarcamesine seems to do....

"reduce abnormal accumulation" via iron balance seems to be a step lower than that.